BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24710689)

  • 1. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 2. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second primary melanomas on treatment with vemurafenib.
    Dalle S; Poulalhon N; Debarbieux S; Thomas L
    Br J Dermatol; 2013 Apr; 168(4):887-8. PubMed ID: 23066856
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib sensitivity skin reaction after ipilimumab.
    Harding JJ; Pulitzer M; Chapman PB
    N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
    [No Abstract]   [Full Text] [Related]  

  • 6. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
    Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
    Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?
    Babacan T; Türkbeyler IH; Balakan O; Pehlivan Y; Suner A; Kısacık B
    Int J Rheum Dis; 2017 Mar; 20(3):398-401. PubMed ID: 24815010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 10. Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.
    van den Brom RR; Mäkelburg AB; Schröder CP; de Vries EG; Hospers GA
    J Clin Oncol; 2015 Dec; 33(36):e133-4. PubMed ID: 24778390
    [No Abstract]   [Full Text] [Related]  

  • 11. Second primary melanomas on treatment with vemurafenib: reply from the authors.
    Fearfield L; Newton-Bishop JA; Sinha R; Edmonds K; Gore ME; Larkin J
    Br J Dermatol; 2013 Apr; 168(4):888-9. PubMed ID: 23066884
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RASopathic alopecia: hair changes associated with vemurafenib therapy.
    Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
    J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
    [No Abstract]   [Full Text] [Related]  

  • 14. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
    Sibaud V; Chevreau C
    Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
    [No Abstract]   [Full Text] [Related]  

  • 16. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of metastatic melanoma with BRAF inhibitors].
    Hafner C
    Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
    [No Abstract]   [Full Text] [Related]  

  • 19. Vemurafenib-induced DRESS.
    Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
    JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
    [No Abstract]   [Full Text] [Related]  

  • 20. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
    Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
    Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.